Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) [Trend Analysis] moved down reacts as active mover, shares a decrease -10.31% to traded at $45.30 and the percentage gap between open changing to regular change was -0.73%. Agios Pharmaceuticals, Inc. (AGIO) released that new clinical and preclinical data for AG-348 and AG-519 will be presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
In total, five abstracts led by Agios and collaborators describing new clinical and preclinical data from the company’s rare genetic metabolic disorders program, including three oral presentations, have been accepted for presentation at EHA. AG-348 is in an ongoing Phase 2 study (DRIVE PK) in adults with pyruvate kinase (PK) deficiency. AG-519 is in an ongoing Phase 1 study in healthy volunteers. The firm’s current ratio calculated as 7.50 for the most recent quarter. The firm past twelve months price to sales ratio was 29.28 and price to cash ratio remained 2.16. The firm has total debt to equity ratio measured as 0.00.
Gerdau S.A. (NYSE:GGB) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -3.68% to $1.57. Goldberg Law PC declared that it is investigating claims of potential misrepresentations by Gerdau S.A. (GGB). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the accusation by Brazil’s federal police that Gerdau evaded $429 million in taxes. The share price of GGB attracts active investors, as stock price of week volatility recorded 9.83%. The stock is going forward to its 52-week low with 98.73% and lagging behind from its 52-week high price with -50.07%.
Inovalon Holdings, Inc. (NASDAQ:INOV) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.84% to close at $18.22 with the total traded volume of 579968 shares. Inovalon (INOV) released that it has reached an contract with Bristol-Myers Squibb (BMY), a global BioPharma company, to bring Inovalon and Avalere’s combined capabilities to bear on supporting real-world outcomes and value-based contracting initiatives. The engagement will leverage the capabilities of Inovalon’s data platforms and Avalere’s extensive industry experience, to support Bristol-Myers Squibb’s real-world outcomes and value-based contracting initiatives.
The application of advanced predictive analytics modeling and large scale real-world outcomes analyses will support consideration of value-based contracts with innovative payers. Inovalon’s national-scale clinical and quality outcomes platforms will allow for real-world insight into the monitoring, reporting, administration, and improvement of outcomes. The firm has institutional ownership of 60.50%, while insider ownership included 0.80%. Its price to sales ratio ended at 6.08. INOV attains analyst recommendation of 2.40 with week performance of 8.84%.